Gain-of-Function R225W Mutation in Human AMPKγ3 Causing Increased Glycogen and Decreased Triglyceride in Skeletal Muscle

Background AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme that is evolutionarily conserved from yeast to mammals and functions to maintain cellular and whole body energy homeostasis. Studies in experimental animals demonstrate that activation of AMPK in skeletal muscle protects against insulin resistance, type 2 diabetes and obesity. The regulatory γ3 subunit of AMPK is expressed exclusively in skeletal muscle; however, its importance in controlling overall AMPK activity is unknown. While evidence is emerging that gamma subunit mutations interfere specifically with AMP activation, there remains some controversy regarding the impact of gamma subunit mutations [1]–[3]. Here we report the first gain-of-function mutation in the muscle-specific regulatory γ3 subunit in humans. Methods and Findings We sequenced the exons and splice junctions of the AMPK γ3 gene (PRKAG3) in 761 obese and 759 lean individuals, identifying 87 sequence variants including a novel R225W mutation in subjects from two unrelated families. The γ3 R225W mutation is homologous in location to the γ2R302Q mutation in patients with Wolf-Parkinson-White syndrome and to the γ3R225Q mutation originally linked to an increase in muscle glycogen content in purebred Hampshire Rendement Napole (RN-) pigs. We demonstrate in differentiated muscle satellite cells obtained from the vastus lateralis of R225W carriers that the mutation is associated with an approximate doubling of both basal and AMP-activated AMPK activities. Moreover, subjects bearing the R225W mutation exhibit a ∼90% increase of skeletal muscle glycogen content and a ∼30% decrease in intramuscular triglyceride (IMTG). Conclusions We have identified for the first time a mutation in the skeletal muscle-specific regulatory γ3 subunit of AMPK in humans. The γ3R225W mutation has significant functional effects as demonstrated by increases in basal and AMP-activated AMPK activities, increased muscle glycogen and decreased IMTG. Overall, these findings are consistent with an important regulatory role for AMPK γ3 in human muscle energy metabolism.

[1]  Roded Sharan,et al.  Medical sequencing at the extremes of human body mass. , 2006, American journal of human genetics.

[2]  J. Wojtaszewski,et al.  Predominant α2/β2/γ3 AMPK activation during exercise in human skeletal muscle , 2006, The Journal of physiology.

[3]  N. Fujii,et al.  AMP-activated protein kinase and the regulation of glucose transport. , 2006, American journal of physiology. Endocrinology and metabolism.

[4]  N. Fujii,et al.  Muscle-specific overexpression of wild type and R225Q mutant AMP-activated protein kinase gamma3-subunit differentially regulates glycogen accumulation. , 2006, American journal of physiology. Endocrinology and metabolism.

[5]  G. Lopaschuk,et al.  AMPK alterations in cardiac physiology and pathology: enemy or ally? , 2006, The Journal of physiology.

[6]  D. Hardie,et al.  AMPK: a key sensor of fuel and energy status in skeletal muscle. , 2006, Physiology.

[7]  Wendy S. Schackwitz,et al.  A PYY Q62P variant linked to human obesity. , 2006, Human molecular genetics.

[8]  J. Zierath,et al.  Changes in Exercise-Induced Gene Expression in 5′-AMP–Activated Protein Kinase γ3–Null and γ3 R225Q Transgenic Mice , 2005 .

[9]  B. Burwinkel,et al.  Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. , 2005, American journal of human genetics.

[10]  F. Dela,et al.  5′AMP activated protein kinase expression in human skeletal muscle: effects of strength training and type 2 diabetes , 2005, The Journal of physiology.

[11]  J. Zierath,et al.  Changes in exercise-induced gene expression in 5'-AMP-activated protein kinase gamma3-null and gamma3 R225Q transgenic mice. , 2005, Diabetes.

[12]  D. Hardie,et al.  AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. , 2005, Cell metabolism.

[13]  G. Hjälm,et al.  The 5′-AMP-activated Protein Kinase γ3 Isoform Has a Key Role in Carbohydrate and Lipid Metabolism in Glycolytic Skeletal Muscle* , 2004, Journal of Biological Chemistry.

[14]  J. Hedegaard,et al.  UDP‐Glucose pyrophosphorylase is upregulated in carriers of the porcine RN− mutation in the AMP‐activated protein kinase , 2004, Proteomics.

[15]  D. Hardie,et al.  5'-AMP-activated protein kinase activity and protein expression are regulated by endurance training in human skeletal muscle. , 2004, American journal of physiology. Endocrinology and metabolism.

[16]  G. Hjälm,et al.  Expression profiling of the γ-subunit isoforms of AMP-activated protein kinase suggests a major role for γ3 in white skeletal muscle , 2004 .

[17]  D. Hardie,et al.  CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. , 2004, The Journal of clinical investigation.

[18]  J. Zierath,et al.  Expression profiling of the gamma-subunit isoforms of AMP-activated protein kinase suggests a major role for gamma3 in white skeletal muscle. , 2004, American journal of physiology. Endocrinology and metabolism.

[19]  David Carling,et al.  The AMP-activated protein kinase cascade--a unifying system for energy control. , 2004, Trends in biochemical sciences.

[20]  Henriette Pilegaard,et al.  5'-AMP-activated protein kinase activity and subunit expression in exercise-trained human skeletal muscle. , 2003, Journal of applied physiology.

[21]  L. Andersson Identification and characterization of AMPK gamma 3 mutations in the pig. , 2003, Biochemical Society transactions.

[22]  D. Carling,et al.  Functional Analysis of Mutations in the γ2 Subunit of AMP-activated Protein Kinase Associated with Cardiac Hypertrophy and Wolff-Parkinson-White Syndrome* , 2002, The Journal of Biological Chemistry.

[23]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[24]  David Carling,et al.  The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[25]  O. Pedersen,et al.  Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. , 2002, Diabetes.

[26]  Olle Ljunqvist,et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.

[27]  S. Henikoff,et al.  Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.

[28]  J. Seidman,et al.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. , 2002, The Journal of clinical investigation.

[29]  J. Seger,et al.  Novel PRKAG2 Mutation Responsible for the Genetic Syndrome of Ventricular Preexcitation and Conduction System Disease With Childhood Onset and Absence of Cardiac Hypertrophy , 2001, Circulation.

[30]  L. Fananapazir,et al.  Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. , 2001, The New England journal of medicine.

[31]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[32]  B. Kemp,et al.  An activating mutation in the γ1 subunit of the AMP‐activated protein kinase , 2001 .

[33]  G. Shulman,et al.  Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. , 2001, Diabetes.

[34]  L. Andersson Identification and characterization of AMPK γ3 mutations in the pig , 2001 .

[35]  B. Kemp,et al.  An activating mutation in the gamma1 subunit of the AMP-activated protein kinase. , 2001, FEBS letters.

[36]  O. Pedersen,et al.  Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. , 2001, Diabetes.

[37]  T. Lang,et al.  Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant gamma2 subunit of 5'-AMP-activated protein kinase, to human chromosome 7q36. , 2000, Genomics.

[38]  C. Rogel-Gaillard,et al.  A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. , 2000, Science.

[39]  D. Carling,et al.  Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. , 2000, The Biochemical journal.

[40]  D. Hardie,et al.  Analysis of the role of the AMP-activated protein kinase in the response to cellular stress. , 2000, Methods in molecular biology.

[41]  D. Hardie,et al.  AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes. , 1999, American journal of physiology. Endocrinology and metabolism.

[42]  B. Kemp,et al.  Functional Domains of the α1 Catalytic Subunit of the AMP-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.

[43]  D. Hardie,et al.  The AMP-activated protein kinase--fuel gauge of the mammalian cell? , 1997, European journal of biochemistry.

[44]  K. Ingham Precipitation of proteins with polyethylene glycol. , 1990, Methods in enzymology.

[45]  D. Carling,et al.  Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. , 1989, European journal of biochemistry.